320 related articles for article (PubMed ID: 35693589)
1. Bone metastases in non-small cell lung cancer: a narrative review.
Knapp BJ; Devarakonda S; Govindan R
J Thorac Dis; 2022 May; 14(5):1696-1712. PubMed ID: 35693589
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates and other bone agents for breast cancer.
Wong MH; Stockler MR; Pavlakis N
Cochrane Database Syst Rev; 2012 Feb; (2):CD003474. PubMed ID: 22336790
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
4. Bone-targeted therapy use in patients with bone metastases from lung cancer: A systematic review of randomized controlled trials.
LeVasseur N; Clemons M; Hutton B; Shorr R; Jacobs C
Cancer Treat Rev; 2016 Nov; 50():183-193. PubMed ID: 27716496
[TBL] [Abstract][Full Text] [Related]
5. Effect of Bisphosphonates, Denosumab, and Radioisotopes on Bone Pain and Quality of Life in Patients with Non-Small Cell Lung Cancer and Bone Metastases: A Systematic Review.
Hendriks LE; Hermans BC; van den Beuken-van Everdingen MH; Hochstenbag MM; Dingemans AM
J Thorac Oncol; 2016 Feb; 11(2):155-73. PubMed ID: 26718881
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
7. Systematic review of the clinical effectiveness and cost-effectiveness, and economic evaluation, of denosumab for the treatment of bone metastases from solid tumours.
Ford J; Cummins E; Sharma P; Elders A; Stewart F; Johnston R; Royle P; Jones R; Mulatero C; Todd R; Mowatt G
Health Technol Assess; 2013 Jul; 17(29):1-386. PubMed ID: 23870108
[TBL] [Abstract][Full Text] [Related]
8. Skeletal morbidity in lung cancer patients with bone metastases: demonstrating the need for early diagnosis and treatment with bisphosphonates.
Langer C; Hirsh V
Lung Cancer; 2010 Jan; 67(1):4-11. PubMed ID: 19939491
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for skeletal-related events (SREs) and factors affecting SRE-free survival for nonsmall cell lung cancer patients with bone metastases.
Ulas A; Bilici A; Durnali A; Tokluoglu S; Akinci S; Silay K; Oksuzoglu B; Alkis N
Tumour Biol; 2016 Jan; 37(1):1131-40. PubMed ID: 26276360
[TBL] [Abstract][Full Text] [Related]
10. Incidence and consequences of bone metastases in lung cancer patients.
Kuchuk M; Addison CL; Clemons M; Kuchuk I; Wheatley-Price P
J Bone Oncol; 2013 Feb; 2(1):22-9. PubMed ID: 26909268
[TBL] [Abstract][Full Text] [Related]
11. Skeletal metastases in non-small cell lung cancer: a retrospective study.
Tsuya A; Kurata T; Tamura K; Fukuoka M
Lung Cancer; 2007 Aug; 57(2):229-32. PubMed ID: 17451841
[TBL] [Abstract][Full Text] [Related]
12. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
13. Does denosumab offer survival benefits? -Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors.
Cao Y; Afzal MZ; Shirai K
J Thorac Dis; 2021 Aug; 13(8):4668-4677. PubMed ID: 34527308
[TBL] [Abstract][Full Text] [Related]
14. The Therapeutic Effect and Clinical Outcome of Immune Checkpoint Inhibitors on Bone Metastasis in Advanced Non-Small-Cell Lung Cancer.
Asano Y; Yamamoto N; Demura S; Hayashi K; Takeuchi A; Kato S; Miwa S; Igarashi K; Higuchi T; Yonezawa H; Araki Y; Morinaga S; Saito S; Sone T; Kasahara K; Tsuchiya H
Front Oncol; 2022; 12():871675. PubMed ID: 35433422
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab monotherapy or combination therapy for bone metastases in advanced non-small cell lung cancer: a real-world retrospective study.
Qiang H; Lei Y; Shen Y; Li J; Zhong H; Zhong R; Zhang X; Chang Q; Lu J; Feng H; Zhu Y; Addeo A; Banna GL; Oh IJ; Qian J; Chu T
Transl Lung Cancer Res; 2022 Jan; 11(1):87-99. PubMed ID: 35242630
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent.
Zhu J; Li R; Tiselius E; Roudi R; Teghararian O; Suo C; Song H
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011300. PubMed ID: 29247502
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Li W; Jiang J; Huang L; Long F
Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
[TBL] [Abstract][Full Text] [Related]
18. Bone metastases and non-small cell lung cancer: from bisphosphonates to targeted therapy.
Rossi A; Gridelli C; Ricciardi S; de Marinis F
Curr Med Chem; 2012; 19(32):5524-35. PubMed ID: 22963665
[TBL] [Abstract][Full Text] [Related]
19. Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma-A Systematic Review.
Brouns A; Dursun S; Bootsma G; Dingemans AC; Hendriks L
Cancers (Basel); 2021 Jun; 13(13):. PubMed ID: 34201833
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]